| Japanese |
|---|
| Title | 心筋脂肪酸代謝イメージング剤β-メチル-p-(123I)-ヨードフェニルペンタデカン酸の第2相臨床試験 - 投与量および適応疾患の検討 - |
|---|
| Subtitle | 原著 |
|---|
| Authors | 鳥塚莞爾*, 米倉義晴**, 西村恒彦***, 玉木長良**, 植原敏勇*** |
|---|
| Authors(kana) | |
|---|
| Organization | *福井医科大学, **京都大学医学部核医学科, ***国立循環器病センター放射線診療部 |
|---|
| Journal | 核医学 |
|---|
| Volume | 29 |
|---|
| Number | 3 |
|---|
| Page | 305-317 |
|---|
| Year/Month | 1992/3 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」各種心疾患197例を対象に心筋脂肪酸代謝イメージング剤β-メチル-p-(123I)-ヨードフェニルペンタデカン酸の第2相臨床試験を実施した. 早期像と後期像を比較すると, 虚血性心疾患91例中88%にて本剤の経時的な心筋内分布の変化はみられず, 一方, 肥大型心筋症では55例中45%において“Washout”または“Fill-in”などの分布の変化がみられた. 201Tlと比較された165例中56%において本剤の方が201Tlより著しい集積低下を示し, 201Tlの方が集積低下が著しかった症例は4%のみであった. 前者の乖離は特に亜急性期(発症後15〜30日)の心筋梗塞(83%)や肥大型心筋症(73%)で高頻度にみられた. 全解析対象194例中93%で良好な心筋SPECT像が得られたが, 心筋症では虚血性心疾患に比し画質が不良であった. 投与量は111MBqを標準とした74〜148MBqが適当であると考えられた. 本剤は安全性に問題はなく, 心筋脂肪酸代謝の評価に有用な放射性医薬品であることが示された. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | β-methyl-p-iodophenyl-pentadecanoic acid(123I-BMIPP), Myocardial fatty acid metabolism, Phase 2 study, Heart disease. |
|---|
| English |
|---|
| Title | Phase 2 Study of β-Methyl-p-(123I)-Iodophenyl-Pentadecanoic Acid, a Myocardial Imaging Agent for Evaluating Myocardial Fatty Acid Metabolism |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Kanji TORIZUKA*, Yoshiharu YONEKURA**, Tsunehiko NISHIMURA***, Nagara TAMAKI**, Toshiisa UEHARA*** |
|---|
| Authors(kana) | |
|---|
| Organization | *Fukui Medical School, **Department of Nuclear Medicine, Faculty of Medicine, Kyoto University, ***Department of Radiology, National Cardiovascular Center |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 29 |
|---|
| Number | 3 |
|---|
| Page | 305-317 |
|---|
| Year/Month | 1992/3 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]A phase 2 study of β-methyl-p-(123I)-iodophenyl-pentadecanoic acid (123I-BMIPP), a myocardial imaging agent developed for evaluating myocardial fatty acid metabolism, was performed in 197 patients with various heart diseases. The myocardial distribution of 123I-BMIPP did not change from early to late images in 88% of 91 patients with ischemic heart disease (IHD), while washout and/or fill-in were observed in 45% of 55 patients with hypertrophic cardiomyopathy (HCM). In comparison with 201Tl in 165 patients with various heart diseases, the decrease in uptake was more profound with BMIPP in 56% and with 201Tl in only 4%. 123I-BMIPP showed more severely decreased uptake in 83% of the patients with subacute myocardial infarction (15 to 30 days after the onset) and in 73% of the patients with HCM. High-quality SPECT images were obtained with 123I-BMIPP in 93% of 194 patients analyzed. However, the image quality in cardiomyopathy was inferior to that in IHD. The optimal injection dose range and standard dose of 123I-BMIPP were considered to be 74-148 MBq and 111 MBq, respectively. These findings suggest that 123I-BMIPP myocardial imaging is safe and useful for evaluating myocardial fatty acid metabolism in various heart diseases. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | β-methyl-p-iodophenyl-pentadecanoic acid(123I-BMIPP), Myocardial fatty acid metabolism, Phase 2 study, Heart disease. |
|---|